Navigation Links
Alexza Announces Proposed Public Offering of Common Stock and Warrants
Date:2/16/2012

MOUNTAIN VIEW, Calif., Feb. 16, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.  JMP Securities LLC is acting as the sole book-running manager in the offering.

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Alexza plans to use the net proceeds from the sale of securities primarily for general corporate purposes, including regulatory, clinical trial, research and development, general and administrative and manufacturing expenses.

The offering is being made pursuant to a shelf registration statement on Form S-3 previously declared effective by the Securities and Exchange Commission, or the SEC, on May 20, 2010.  A preliminary prospectus supplement relating to the offering will be filed with the SEC.  When available, copies of the preliminary prospectus supplement relating to the offering and the accompanying base prospectus may be obtained by contacting JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, Attention: Prospectus Department, (415) 835-8985.  A copy of the preliminary prospectus supplement relating to the offering and the accompanying base prospectus may also be accessed on the SEC website, http://www.sec.gov.  Before you invest, you should read the preliminary prospectus supplement and the accompanying base prospectus in that registration statement and other documents Alexza has filed or will file with the SEC for more complete information about Alexza and the offering.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Alexza nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted in August 2011, completed an advisory committee meeting in December 2011, received a notice of extension of the Prescription Drug User Fee Act (PDUFA) goal date in January 2012, and has a new PDUFA goal date of May 4, 2012.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011. 

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the Company's ability to raise additional funds and the potential terms of such potential financings, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

 


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Conn. , Dec. 8, 2016  Boehringer Ingelheim ... 2017 Corporate Equality Index (CEI). This is the ninth ... has been designated as a Best Place to Work ... Foundation, the CEI is a national benchmarking report on ... lesbian, gay, bisexual and transgender (LGBT) employees. ...
(Date:12/8/2016)... Noom, Inc., the leader in mobile health ... only when their members achieve real health outcomes. The ... which typically charges for arbitrary enrollment, participation and engagement ... The company,s ... the empathy of live human coaches to change the ...
(Date:12/8/2016)... CANTEL MEDICAL CORP. (NYSE: CMD ) ... per diluted share, on a 22.1% increase in sales to ... 2016. This compares with net income of $14,254,000, or $0.34 ... quarter ended October 31, 2015. Non-GAAP net ... 2016 to $21,323,000, or $0.51 per diluted share, compared with ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... The Compretta Insurance Agency, a family owned insurance and financial ... Hancock County area, is announcing the launch of a charity effort aimed at raising ... Food Pantry has worked for more than 30 years to meet the food needs ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its ... is one of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. ... companies on both sides of the Atlantic with a mechanism to comply with EU ...
(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry ... Control through a new partnership with Splashtop Inc. This remote control for Android ... to help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning of October 30, ... medical call when he lost control of his patrol car. The vehicle overturned into ... he was transported to Atlanta Medical Center, where he later succumbed to his injuries. ...
Breaking Medicine News(10 mins):